基因组编辑
移码突变
计算生物学
基因组
清脆的
生物
内含子
Cas9
遗传学
RNA编辑
转录激活物样效应核酸酶
人类基因组
锌指核酸酶
RNA剪接
引导RNA
突变
范围(计算机科学)
基因组工程
终止密码子
基因
计算机科学
碱基对
生物信息学
作者
Hong-Xia Zhang,Junyi Duan,Chen Qiubing,磊鑫 林,Yizhou Zhang,Min Duan,Didi Chen,Xi Liu,Linyang Wu,Guoquan Wang,Ying Zhang,Hao Yin
标识
DOI:10.15302/vita.2026.09.0074
摘要
Genome editing has traditionally been regarded as permanent genomic alterations. While this durability underpins lasting therapeutic benefit, it also raises safety concerns due to the risk of potentially irreversible adverse effects. Here, we demonstrate the feasibility of reversible genome editing in vitro and in vivo using diverse platforms, including CRISPR-Cas9, base editors (BEs), and prime editors (PEs). Specifically, we show that a cytosine base editor (CBE) can restore normal splicing by reversing adenine base editor (ABE)-induced intron retention, and that PE can correct frameshift mutations generated by Cas9 or PE in animals. These genomic restorations led to sustained recovery of protein expression in vivo. Furthermore, we achieved reversible editing of clinically relevant human genes, including ANGPTL3, SERPINA1, TTR, and PCSK9, through targeted correction of diverse mutation types, providing an “antidote” to the genome editing events. Together, these findings establish a framework for reversible genome editing as a generalizable strategy to enhance the safety, flexibility, and therapeutic scope of genome editing.
科研通智能强力驱动
Strongly Powered by AbleSci AI